Svartz N
King Gustaf V Research Institute, Stockholm, Sweden.
Am J Gastroenterol. 1988 May;83(5):497-503.
In summing up: salazopyrin is an effective drug, particularly in ulcerative colitis. Serious adverse effects are remarkably rare. Salazopyrin provoked an improvement in 75-80% of cases of UC. It is excellently adapted for long-term treatment and, in this respect, is clearly superior to corticosteroids. It prevents relapses, particularly if the dosage is increased. The main indication for corticosteroids in UC is for acute attacks early in the course of the disease and to influence allergic symptoms during the disease. For acute swelling of the rectum, local treatment with corticosteroids or salazopyrin is often effective. Adverse effects occur in about 15% of cases treated with salazopyrin. They are due primarily to hypersensitivity to the drug. With very few exceptions, they disappear spontaneously or are controlled by corticosteroids or by some other treatment. The allergic pulmonary changes may give rise to a modest dyspnea, which is not fatal. The cyanotic and the yellow-coloring of the skin are harmless side effects. As to sulfa crystals in the kidneys and the urine, for the most part, they can be avoided by simple treatment. Agranulocytosis is a rare complication in the course of treatment with salazopyrin. During the 35 yr that the drug has been used, only 14 cases have been published in the literature. Of this number, three have died, but the treatment of the agranulocytosis is known in only one of them. Nonpublished cases probably exist, but this number does not seem to be great in my experience. In comparison with many other drugs (certain chemotherapeutics and antibiotics), the frequency of serious side effects caused by salazopyrin is remarkably low.
柳氮磺胺吡啶是一种有效的药物,尤其在治疗溃疡性结肠炎方面。严重的不良反应极为罕见。柳氮磺胺吡啶能使75%至80%的溃疡性结肠炎病例病情改善。它非常适合长期治疗,在这方面明显优于皮质类固醇。它能预防复发,尤其是在增加剂量的情况下。皮质类固醇在溃疡性结肠炎中的主要适应证是疾病早期的急性发作以及影响疾病期间的过敏症状。对于直肠急性肿胀,局部使用皮质类固醇或柳氮磺胺吡啶治疗通常有效。接受柳氮磺胺吡啶治疗的病例中约15%会出现不良反应。这些不良反应主要是由于对该药物过敏。除极少数情况外,它们会自行消失或通过皮质类固醇或其他一些治疗得到控制。过敏性肺部改变可能会引起轻度呼吸困难,但不会致命。皮肤发绀和发黄是无害的副作用。至于肾脏和尿液中的磺胺结晶,在很大程度上,通过简单治疗即可避免。粒细胞缺乏症是柳氮磺胺吡啶治疗过程中罕见的并发症。在该药物使用的35年中,文献中仅发表了14例。其中3例死亡,但仅1例已知粒细胞缺乏症的治疗情况。可能存在未发表的病例,但根据我的经验,这个数字似乎不大。与许多其他药物(某些化疗药物和抗生素)相比,柳氮磺胺吡啶引起严重副作用的频率极低。